Fusion constructs and methods of using thereof
AssigneePrecigen, Inc.
InventorsHelen Sabzevari, Simon Metenou, ChangHung Chen, Rutul R. Shah
Life of this patent
Estimating the term…
Abstract
Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-β trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
Claims17
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a fusion protein comprising:
- (a) an antibody, or an antigen-binding fragment or variant thereof, that specifically binds to programmed cell death protein-1 (PD-1) and comprises either:
- (1) a VH region having the sequence of SEQ ID NO:
- 6 and a VL region having the sequence of SEQ ID NO:
- 12;
- or
- (ii) a VH region having the sequence of SEQ ID NO:
- 7 and a VL region having the sequence of SEQ ID NO:
- 13;
- and
- (b) a transforming growth factor beta (TGF-β) cytokine trap having the sequence of SEQ ID NO:
- 14;
- wherein the components of (a) and (b) are connected by a peptide linker and the cancer is colorectal cancer, head and neck cancer, or ovarian cancer.
Dependencies are inferred from the claim text.